BMS investing in Biocon’s oral insulin program

In a news release on 17 November 2012, Biocon of India announced that they have reached a deal with Bristol Myers Squibb to partially fund a phase 2 program for IN-105, an oral insulin, to be conducted in the USA and Europe.  Under the agreement, BMS will support Biocon in redesigning studies in the phase 2 program, and after 2 years BMS will have the option to develop and market the product outside India. 

The Biocon oral insulin program was previously partnered with Pfizer, who pulled out of the deal earlier in 2012.

Link to the B I O C O N release.

Comments are closed.